BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Shareholder Director NominationsItem 5.08Shareholder Director Nominations.
On February 6, 2018, the Board of Directors of Biocept, Inc. (the “Company”) set June 7, 2018 as the date for the Company’s 2018 Annual Meeting of Stockholders (the “Annual Meeting”).
The date of the Annual Meeting is changing by more than 30 days from the anniversary date of the Company’s 2017 Annual Meeting of Stockholders, and therefore the Company is providing this information in accordance with Rule 14a−5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).Because the date of the Annual Meeting is being delayed by more than 30 days from the anniversary date of the Company’s 2017 Annual Meeting of Stockholders, the Company believes that January 3, 2018, which is 120 days prior to the time before it expects to begin to print and send proxy materials for the Annual Meeting, is a reasonable time before it expects to begin to print and send proxy materials for the Annual Meeting.Therefore, any stockholder proposal intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting to Rule 14a-8 under the Exchange Act, must have been received by the Company’s Secretary on or before the close of business on January 3, 2018.
to the Company’s Amended and Restated Bylaws, a stockholder who wishes to make a proposal at the Annual Meeting without including the proposal in the Company’s proxy materials for the Annual Meeting must notify the Company no later than the close of business on February 22, 2018, which is the 10th day following the day on which notice of the date of the Annual Meeting was publicly disclosed.The Company’s Amended and Restated Bylaws specify certain requirements regarding the form and content of such a notice.
About BIOCEPT, INC. (NASDAQ:BIOC)
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.